

**What is claimed is:**

1. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of an anti-C3b(i) antibody.
2. A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount a nucleic acid sequence encoding an anti-C3b(i) antibody.
3. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is immunospecific specific for C3b(i) covalently linked to IgM or IgG antibody on cancer cells.
4. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is immunospecific for C3b(i) covalently linked to proteins or lipids on cancer cells.
5. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.
6. The method of Claim 1 or 2 in which the anti-C3b(i) antibody is a monoclonal antibody.
7. The method of Claim 1 or 2 further comprising administering IgM antibody or IgG antibody.
8. The method Claim 1 or 2 further comprising administering one or more complement components.
9. The method of Claim 5 in which the effector cell is selected from the group consisting of: lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, natural killer cells and erythrocytes.
10. The method of Claim 5 in which the effector cell is an erythrocyte.
11. The method of Claim 5 in which the antigen is selected from the group consisting of: CR1, CR2, CR3, CR4, CD16, CD32, CD64 and CD89.

12. The method of Claim 5 wherein the bispecific antibody is bound *ex vivo* to the effector cell.
13. The method of Claim 1 or 2 in which the antibody is conjugated to a therapeutic agent.
14. The method of Claim 1 or 2 further comprising administering IgM or IgG antibody and one or more complement components.
15. The method of Claim 1 or 2 in which the antibody is conjugated to a detectable agent.
16. The method of Claim 1 or 2 further comprising administering plasma.
17. The method of Claim 1 or 2 further comprising administering one or more antibodies immunospecific for a cancer cell antigen.
18. The method of Claim 1 or 2 further comprising administering one or more antibodies immunospecific for a cancer cell antigen and one or more complement components.
19. The method of Claim 6 in which the monoclonal antibody is a human or humanized monoclonal antibody.
20. The method of claim 1 or 2 in which the animal is a human.
21. The method of claim 7 in which the animal is a human.
22. The method of claim 17 in which the animal is a human.

NY2 - 1143461.3